북미 급성 관상동맥증후군 시장, 유형별(비ST 상승 심근경색, ST 상승 심근경색, 불안정 협심증), 진단 (스트레스 검사, 혈액 검사, 영상 검사 및 기타), 치료 (약물 및 수술), 최종 사용자(병원 및 진료소, 진단 센터, 학술 기관 및 기타) - 업계 동향 및 2029년까지의 전망.
북미 급성 관상 동맥 증후군 시장 분석 및 통찰력
북미 급성 관상동맥증후군 시장은 2022년에서 2029년의 예측 기간 동안 상당한 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년에서 2029년의 예측 기간 동안 5.4%의 CAGR로 성장하고 있으며 2029년까지 5,910.97백만 달러에 도달할 것으로 예상된다고 분석했습니다. 급성 관상동맥증후군 시장 성장을 견인하는 주요 요인은 관상동맥질환, 허혈성 심장질환, 혈관질환과 같은 만성 질환의 유병률 증가, 노인 인구 증가, 시장 참여자들이 제공하는 광범위한 제품 범위로 인해 급성 관상동맥증후군 시장이 미래에 성장할 것으로 예상됩니다.
급성 관상동맥증후군은 심장으로 가는 혈류가 감소하는 질병군을 말합니다. ACS와 관련된 상태에는 ST 상승 심근경색(STEMI), 비ST 상승 심근경색(NSTEMI), 불안정 협심증이 있습니다. 이것은 관상동맥 심장병(CHD)의 한 유형으로, 35세 이상의 사람들의 총 사망자의 3분의 1을 차지합니다. 일부 형태의 CHD는 무증상일 수 있지만 ACS는 항상 증상이 있습니다.
급성 관상동맥증후군(ACS)은 관상동맥심장질환(CHD)의 증상이며 일반적으로 관상동맥의 플라그 파괴(죽상경화증)의 결과입니다. 이 질환의 일반적인 위험 요인은 흡연, 고혈압, 당뇨병, 고지혈증, 신체 활동 부족, 가족 비만 및 영양 부족입니다. 코카인 남용은 또한 혈관경련으로 이어질 수 있습니다. 조기 심근경색(55세)의 가족력도 고위험 요인입니다.
북미 급성 관상동맥증후군 시장 보고서는 시장 점유율, 새로운 개발, 국내 및 지역 시장 참여자의 영향에 대한 세부 정보를 제공하고, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서 기회를 분석합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.
보고서 메트릭 |
세부 |
예측 기간 |
2022년부터 2029년까지 |
기준 연도 |
2021 |
역사적 연도 |
2020 (2019-2014까지 사용자 정의 가능) |
양적 단위 |
수익은 백만 달러, 가격은 미화로 표시됨 |
다루는 세그먼트 |
By Type (Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction, and Unstable Angina), Diagnosis (Stress Test, Blood Tests, Imaging and Others), Treatment (Medication and Surgery), End User (Hospitals and Clinics, Diagnostic Centers, Academic Institutes and Others) |
Countries Covered |
U.S., Canada and Mexico in North America. |
Market Players Covered |
AstraZeneca, Daiichi Sankyo company, Johnson & Johnson Service Inc., Amgen Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc, Sanofi, CSL Behring, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter, Dr. Reddy’s Laboratories, Merck & Co., Inc. and Novartis AG and among others. |
Acute Coronary Syndrome Market Dynamics
Drivers
- Rise in prevalence of chronic diseases, such as Coronary Artery Disease, Ischemic Heart Disease, and Vascular Diseases
As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence of chronic heart and vascular diseases would help in finding novel solutions, and developing the cardiology and vascular devices would aid in more collaborations and partnerships with market players in the U.S., Europe, and Asia Pacific region. This signifies that the increase in research and development investment for the discovery and development of treatments of acute coronary syndrome boosts the market growth.
- Growing Geriatric Population
The number of elderly people reporting respective cardiovascular diseases is high. Owing to this, it is anticipated that the ever-increasing geriatric population, which is expected to rise in future years worldwide mainly in North America & Asia-Pacific region, creates an opportunity for market growth in the forecast period.
- Wide Range of Products Offered by Market Players
Strategic product launches and collaborations done by major companies in interventional cardiology and peripheral vascular devices have opened up an opportunity to expand their business in various regions. This strategy is allowing the companies to strengthen their footprints in the market. Therefore, it is predicted that strategic initiative is the golden opportunity for the market players to accelerate their revenue growth in the market.
Opportunities
- Surge in Technological Advancements for Cardiovascular Disease
As technology advances rapidly, it improves how one manages cardiovascular diseases. In addition, recent healthcare monitoring applications and gadgets have enhanced the connection between patients and healthcare providers to update treatment plans and improve health outcomes. Thus, this is expected to create a significant opportunity for the North America acute coronary syndrome market in the forecast period.
Also, Governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.
Restraints/Challenges
Rise in cost of the therapeutic surgery and lack of accessibility of disease management services and support in low economic countries are the restrains and challenges for the growth of acute coronary syndrome market.
The increased intricacy and cost of the cardiology devices and robust investments would increase the costs. The increased cost would result in delayed treatment of the patients in hospitals and clinics and clearance of these product is very rigorous and time-consuming many of the products find it difficult to get approved due to not complying with the regulations which may hamper the market growth.
This acute coronary syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on acute coronary syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In October, Novartis AG expanded a new digital healthcare solution across chronic heart disease management. Co-developed with China’s internet multinational Tencent, together with leading Chinese medical organizations, the digital healthcare solution is now broadening its scope to cardiovascular disease in general – supporting patients from pre-diagnosis to hospital discharge and ongoing at-home disease management. It helps patients with heart failure to easily accommodate disease management into everyday living, alerting them to signs of disease worsening. Patients can then take early action to avoid re-hospitalization, in a country where heart disease is on the rise.
North America Acute Coronary Syndrome Market Scope
North America acute coronary syndrome market is categorized based on type, diagnosis, treatment and end user. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Non-St-Elevation Myocardial Infarction
- St-Elevation Myocardial Infarction
- Unstable Angina
On the basis of type, the North America acute coronary syndrome market is segmented into non-St-elevation myocardial infarction, St-elevation myocardial infarction and unstable angina.
Diagnosis
- Stress Test
- Blood Tests
- Imaging
- Others
On the basis of diagnosis, the North America acute coronary syndrome market is segmented into stress test, blood test, imagining and others.
Treatment
- Medication
- Surgery
On the basis of treatment, the North America acute coronary syndrome market is segmented into medication and surgery.
End User
- Hospitals and Clinics
- Diagnostic Centers
- Academic Institutes
- Others
On the basis of end user, the North America acute coronary syndrome market is segmented into hospitals and clinics, diagnostic centers, academic institutes and others.
Acute Coronary Syndrome Market Regional Analysis/Insights
North America acute coronary syndrome market is further segmented into major countries including the U.S., Canada, and Mexico.
The U.S. in North America dominates the acute coronary market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in the country.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Acute Coronary Syndrome Market Share Analysis
North America Acute coronary syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to acute coronary syndrome market.
북미 급성 관상동맥증후군 시장에서 활동하는 대표적인 기업으로는 Movianto(미국), Sharp(미국), Thermo Fisher Scientific Inc.(미국), Catalent, Inc(미국), PCI Pharma Services(미국), Almac Group(영국), PAREXEL International Corporation(미국), Bionical Ltd.(영국), Alium Medical Limited(영국), MYODERM(영국), Clinigen Group plc(영국), Ancillare, LP(미국), SIRO Clinpharm(인도), CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC.(미국), Biocair(영국) 등이 있습니다.
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ACUTE CORONARY SYNDROME MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN PREVALENCE OF CHRONIC DISEASES, SUCH AS CORONARY ARTERY DISEASE, ISCHEMIC HEART DISEASE, AND VASCULAR DISEASES
6.1.2 GROWING GERIATRIC POPULATION
6.1.3 WIDE RANGE OF PRODUCTS OFFERED BY MARKET PLAYERS
6.1.4 IMPROVING HEALTHCARE INFRASTRUCTURE AND REIMBURSEMENT POLICIES
6.2 RESTRAINTS
6.2.1 RISE IN COST OF THERAPEUTIC SURGERY
6.2.2 STRINGENT RULES & REGULATIONS
6.3 OPPORTUNITIES
6.3.1 SURGE IN TECHNOLOGICAL ADVANCEMENTS FOR CARDIOVASCULAR DISEASE
6.3.2 RISING HEALTHCARE EXPENDITURE
6.3.3 INCREASED REIMBURSEMENT POLICIES
6.3.4 RISING DISEASE MANAGEMENT PROGRAMS
6.4 CHALLENGES
6.4.1 LACK OF ACCESSIBILITY OF SERVICES
6.4.2 LONG PROCESS OF APPROVAL BY REGULATORY BODIES
7 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TYPE
7.1 OVERVIEW
7.2 NON-ST- ELEVATION MYOCARDIAL INFARCTION
7.3 ST-ELEVATION MYOCARDIAL INFARCTION
7.4 UNSTABLE ANGINA
8 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS
8.1 OVERVIEW
8.2 STRESS TEST
8.3 BLOOD TEST
8.4 IMAGING
8.5 OTHERS
9 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT
9.1 OVERVIEW
9.2 MEDICATION
9.3 SURGERY
10 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS AND CLINICS
10.3 DIAGNOSTIC CENTERS
10.4 ACADEMIC INSTITUTES
10.5 OTHERS
11 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 NOVARTIS AG
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.1.5.1 PRODUCT EXPANSION
14.1.5.2 COLLABRATION
14.2 ASTRA ZENECA
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.2.5.1 ACQUISITION
14.3 AMGEN INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 SANOFI
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.4.5.1 ACQUISITION
14.5 BAXTER
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 DR. REDDY’S LABORATORIES LTD.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.6.4.1 ACQUISTION
14.7 PFIZER INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 MERCK & CO., INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENTS
14.8.4.1 EVENT
14.8.4.2 ACQUISTION
14.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.9.3.1 PRODUCT APPROVAL
14.1 CSL
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.10.4.1 ACQUISITION
14.11 DAIICHI SANKYO COMPANY,LIMITED
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.11.4.1 PARTNERSHIP
14.12 JOHNSON & JOHNSON SERVICES, INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.12.4.1 ACQUISITION
14.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT
14.13.4.1 ACQUISITION
14.14 REGENERON PHARMACEUTICALS INC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
표 목록
TABLE 1 LIST OF RECENT PROGRESS OF 3D BIO PRINTING FOR CARDIAC TISSUE ENGINEERING-
TABLE 2 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA NON-ST-ELEVATION MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA ST—ELEVATION MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA UNSTABLE ANGINA IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA STRESS TEST IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA BLOOD TEST IN ACUTE SYNDROME CORONARY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA IMAGING IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA OTHERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA MEDICATION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA SURGERY IN ACUTE CORONARY SYNDROME MARKET, BY REGION 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA HOSPITALS AND CLINICS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA DIAGNOSTIC CENTERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA ACADEMIC INSTITUTES IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA OTHERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION )
TABLE 21 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION )
TABLE 22 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION )
TABLE 23 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 24 U.S. ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION )
TABLE 25 U.S. ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)
TABLE 26 U.S. ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION )
TABLE 27 U.S. ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 CANADA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 CANADA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION )
TABLE 30 CANADA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION )
TABLE 31 CANADA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 MEXICO ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION )
TABLE 33 MEXICO ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION )
TABLE 34 MEXICO ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION )
TABLE 35 MEXICO ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 NORTH AMERICA ACUTE CORONNARY SYNDROME MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA ACUTE CORONARY SYNDROME MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 11 RISING PREVALENCE OF CORONARY ARTERY DISEASE, ISCHEMIC HEART AND VASCULAR DISEASE AS WELL AS GROWING GERIATRIC POPULATION IS DRIVING THE NORTH AMERICA ACUTE CORONARY SYNDROME MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ACUTE CORONARY SYNDROME MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA ACUTE CORONARY SYNDROME MARKET
FIGURE 14 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, 2021
FIGURE 15 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, 2021
FIGURE 19 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 22 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, 2021
FIGURE 23 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, 2022-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 26 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY END USER, 2021
FIGURE 27 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY END USER, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: SNAPSHOT (2021)
FIGURE 31 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2021)
FIGURE 32 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: BY TYPE (2022-2029)
FIGURE 35 NORTH AMERICA ACUTE CORONARY SYNDROME MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.